Financings in Brief: Sonus Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Sonus Pharmaceuticals: Commences initial public offering of 2.85 mil. shares to be sold at a price of $7 per share. Bothell, Washington-based Sonus previously expected to offer 2.5 mil. shares for $10 to $12 each ("The Gray Sheet" Oct. 2, p. 15). Underwriters Hambrecht & Quist, Montgomery Securities, and UBS Securities retain an over-allotment option to purchase up to 427,500 additional shares...